• Renata Jaskula-Sztul has a Masters degree in Cell Biology from the Adam Mickiewicz University in Poznan, Poland and a PhD in Biochemistry from the Institute of Bioorganic Chemistry Polish Academy of Sciences. She completed a two-year postdoctoral training in the Department of Pharmacology followed by an additional three-year postdoctoral fellowship in the Department of Human Oncology at UW-Madison. Since joining the Department of Surgery at UAB she has been working on multiple projects investigating the role of several small molecules in suppression of neuroendocrine cancers growth. Some of these compounds are already in Phase I clinical trials. In addition, she is investigating the tumor suppressor role of the Notch pathway in vitro and in vivo in medullary thyroid cancer. Most recently, she has changed the scientific direction to utilize novel nanomedicine techniques in order to develop targeted cancer therapies. In collaboration with bioengineers she has developed nanoparticles (nanopolimers and unimolecular micelles) conjugated with anticancer drugs specifically targeting neuroendocrine tumor cells and tissues. It is hoped that the multi-functional nanoparticle therapeutics which she is innovating will provide safe, effective treatments that can either augment or supplant surgical operations in the treatment of neuroendocrine cancer.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancerCell Reports.  40. 2022
    2022 High-Throughput Analysis to Identify Activators of Notch SignalingMethods in Molecular Biology.  2472:49-56. 2022
    2021 Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue SurrogatesFrontiers in Endocrinology.  12. 2021
    2021 Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapyCancer Gene Therapy.  28:799-812. 2021
    2021 Corrigendum to: Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment [Surgery. 2020 Jan;167(1):189-196. doi: 10.1016/j.surg.2019.05.092. Epub 2019 Oct 16.PMID: 31629542] (Surgery (2020) 167(1) (189–196), (S0039606019305835), (10.1016/j.surg.2019.05.092))Surgery.  170:351. 2021
    2021 Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical PerformanceThe Oncologist.  26:e608-e621. 2021
    2020 Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumorsCancer Gene Therapy.  27:898-909. 2020
    2020 Dual-targeted extracellular vesicles to facilitate combined therapies for neuroendocrine cancer treatmentPharmaceutics.  12:1-13. 2020
    2020 Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor CellsMolecules.  25. 2020
    2020 Cytochrome P4501B1 in bone marrow is co-expressed with key markers of mesenchymal stem cells. BMS2 cell line models PAH disruption of bone marrow niche development functionsToxicology and Applied Pharmacology.  401. 2020
    2020 Phosphoprotein-based biomarkers as predictors for cancer therapyProceedings of the National Academy of Sciences of USA.  117:18401-18411. 2020
    2020 A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor–guided antibody-drug conjugate: Perspectives on clinical response?Surgery.  167:197-203. 2020
    2020 Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatmentSurgery.  167:189-196. 2020
    2020 Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and ValidationBiotechnology Journal.  15. 2020
    2019 Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitorsCancers.  11. 2019
    2019 Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancersSurgery.  165:64-68. 2019
    2018 Bioprocess development of antibody-drug conjugate production for cancer treatmentPLoS One.  13. 2018
    2018 Notch3 as a novel therapeutic target in metastatic medullary thyroid cancerSurgery.  163:104-111. 2018
    2017 Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1Cancer Medicine.  6:2142-2152. 2017
    2017 Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosisCancer.  123:769-782. 2017
    2017 Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence ImagingAdvanced Functional Materials.  27. 2017
    2017 AB3-loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatmentJournal of Materials Chemistry B.  5:151-159. 2017
    2017 Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivoOncotarget.  8:70828-70840. 2017
    2016 KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapyBiomaterials.  97:22-33. 2016
    2016 Notch1 signaling regulates the aggressiveness of differentiated thyroid cancer and inhibits SERPINE1 expressionClinical Cancer Research.  22:3582-3592. 2016
    2016 Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapyBiomaterials.  91:1-10. 2016
    2015 Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoidsCancer Gene Therapy.  22:496-505. 2015
    2015 Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiationCancer Gene Therapy.  22:410-416. 2015
    2015 Tumor-suppressor role of notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological inductionMolecular Cancer Therapeutics.  14:499-512. 2015
    2014 Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid CancerAnnals of Surgical Oncology.  21:497-504. 2014
    2014 The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growthJournal of Surgical Research.  190:191-197. 2014
    2014 Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivoCancer Gene Therapy.  21:518-525. 2014
    2013 Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapyNanoscale.  5:9924-9933. 2013
    2013 Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growthMolecular Cancer Therapeutics.  12:1276-1287. 2013
    2013 Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivoCancer.  119:774-781. 2013
    2013 Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and NotchNeuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships.  97:57-66. 2013
    2013 Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell lineCancer Medicine.  2:734-743. 2013
    2012 Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapyNanoscale.  4:7185-7193. 2012
    2011 Expression of the active notch1 decreases MTC tumor growth in vivoJournal of Surgical Research.  171:23-27. 2011
    2011 Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell linesGynecologic Oncology.  122:396-401. 2011
    2011 A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinomaThe Oncologist.  16:835-843. 2011
    2011 Identification and validation of Notch pathway activating compounds through a novel high-throughput screening methodCancer.  117:1386-1398. 2011
    2010 Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growthMolecular Cancer Therapeutics.  9:429-437. 2010
    2008 Suberoyl bishydroxamic acid activates Notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinomaAnnals of Surgical Oncology.  15:2600-2605. 2008
    2007 Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cellsJournal of Gastrointestinal Surgery.  11:1515-1520. 2007
    2007 Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cellsThe Oncologist.  12:942-951. 2007
    2005 Reduced DNA repair capacity in laryngeal cancer subjects: A comparison of phenotypic and genotypic resultsAdvances in oto-rhino-laryngology.  62:25-37. 2005
    2003 Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liverToxicology and Applied Pharmacology.  193:84-96. 2003
    2001 Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer riskJournal of Applied Genetics: an international journal of genetics and breeding.  42:223-231. 2001
    2000 Polymorphism in detoxifying enzymesPostepy biochemii.  46:50-59. 2000
    1999 DNA copy number losses are more frequent in primary larynx tumors with lymph node metastases than in tumors without metastasesCancer Genetics.  114:31-34. 1999
    1999 Molecular and cellular alterations in tobacco smoke-associated larynx cancerMutation Research: Genetic Toxicology and Environmental Mutagenesis.  445:259-274. 1999
    1998 Glutathione S-transferase M1 and T1 genotypes and susceptibility to smoking related larynx cancerBiomarkers.  3:149-155. 1998

    Education And Training

  • Doctor of Philosophy in Biochemistry, Adam Mickiewicz University/Poznan 1998
  • Full Name

  • Renata Jaskula-Sztul